James Lennon, DO
Hematology & Oncology · Opelika, ALNPI 1124339338
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 43 manufacturers reported payments, led by Deciphera Pharmaceuticals Inc. at 32.2% of the total. Reporting peaked in 2021 at $3,441 and has fallen 67.3% since, to $1,126 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AL, where the typical reported total is $7,159.
Across 163 payments — averaging $41.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$2K
- Jazz Pharmaceuticals Inc.$1K
- AstraZeneca$329
- Bristol Myers Squibb$251
- Daiichi Sankyo Inc.$217
- Merck$214
- plus $3K from 37 others
What the payments were for
- Consulting fees$3,25048%
- Speaking & faculty fees$1502%
- Food & beverage$3,30749%
- Education$981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,805 in reported general payments places this provider in the 45th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 62 | $839,877 |
| RevlimidLenalidomide | 19 | $330,452 |
| CalquenceAcalabrutinib Maleate | 21 | $306,549 |
| ErleadaApalutamide | 20 | $280,573 |
| VerzenioAbemaciclib | 19 | $275,146 |
| ImbruvicaIbrutinib | 19 | $262,648 |
| TagrissoOsimertinib Mesylate | 12 | $197,251 |
| Lenalidomide | 21 | $191,509 |
| Abiraterone Acetate | 13 | $30,225 |
| EliquisApixaban | 29 | $16,711 |
| Enoxaparin Sodium | 14 | $5,888 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $1,748 |
| Morphine Sulfate ErMorphine Sulfate | 48 | $1,315 |
| Megestrol Acetate | 15 | $1,280 |
| Acyclovir | 35 | $1,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $329 | $503,80033 claims |
| Bristol Myers SquibbRevlimid | $251 | $330,45219 claims |
| Johnson & JohnsonErleada | $148 | $280,57320 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $36 | $275,41133 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $23 | $262,64819 claims |
| PfizerEliquis | $193 | $16,71129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Opelika
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
- Midhun MallaBirmingham$144K
- Robert ConryBirmingham$143K
- David MooneyBirmingham$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.